[1] Sung H, Ferlay J, Siegel RL, et al.  Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.   doi: 10.3322/caac.21660
[2] Olthof EP, van der Aa MA, Adam JA, et al.  The role of lymph nodes in cervical cancer: incidence and identification of lymph node metastases—a literature review[J]. Int J Clin Oncol, 2021, 26(9): 1600-1610.   doi: 10.1007/s10147-021-01980-2
[3] Abu-Rustum NR, Yashar CM, Bean S, et al.  NCCN guidelines insights: cervical cancer, version 1.2020[J]. J Natl Compr Canc Netw, 2020, 18(6): 660-666.   doi: 10.6004/jnccn.2020.0027
[4] Eduardo MG, Campaner AB, Silva MA.  Apoptosis phenomena in squamous cell carcinomas and adenocarcinomas of the uterine cervix[J]. Pathol Oncol Res, 2015, 21(4): 887-892.   doi: 10.1007/s12253-015-9906-y
[5] 全莉梅.  18F-FDG PET/CT在宫颈癌分期及淋巴结转移评估中的应用[J]. 中国妇幼健康研究, 2019, 30(7): 881-884.   doi: 10.3969/j.issn.1673-5293.2019.07.025
Quan LM.  Application of 18F-FDG PET/CT in the evaluation of cervical cancer staging and lymph node metastasis[J]. Chin J Woman Child Health Res, 2019, 30(7): 881-884.   doi: 10.3969/j.issn.1673-5293.2019.07.025
[6] 黄建敏, 潘莉萍, 李冬雪.  PET和PET-CT在宫颈癌中的应用价值[J]. 国际放射医学核医学杂志, 2007, 31(2): 112-114.   doi: 10.3760/cma.j.issn.1673-4114.2007.02.016
Huang JM, Pan LP, Li DX.  The application of PET and PET-CT in cervical cancer[J]. Int J Radiat Med Nuel Med, 2007, 31(2): 112-114.   doi: 10.3760/cma.j.issn.1673-4114.2007.02.016
[7] 卓静, 王冠民, 朱峰, 等.  18氟脱氧葡萄糖发射型正电子断层-计算机断层显像扫描体积代谢参数对晚期宫颈癌同步放化疗效果的预测分析[J]. 中国性科学, 2022, 31(11): 87-91.   doi: 10.3969/j.issn.1672-1993.2022.11.022
Zhuo J, Wang GM, Zhu F, et al.  Predictive analysis of 18F-FDG PET/CT volume metabolism parameters for concurrent chemoradiotherapy in advanced cervical cancer[J]. Chin J Hum Sex, 2022, 31(11): 87-91.   doi: 10.3969/j.issn.1672-1993.2022.11.022
[8] 武科, 徐臣, 孙洪赞.  术前18F-FDG PET/CT显像联合凝血功能参数预测早期宫颈癌复发[J]. 中华核医学与分子影像杂志, 2021, 41(6): 334-340.   doi: 10.3760/cma.j.cn321828-20200322-00117
Wu K, Xu C, Sun HZ.  Predictive value of preoperative 18F-FDG PET/CT imaging combined with coagulation parameters for recurrence in patients with early cervical cancer[J]. Chin J Nucl Med Mol Imaging, 2021, 41(6): 334-340.   doi: 10.3760/cma.j.cn321828-20200322-00117
[9] Kitajima K, Suenaga Y, Ueno Y, et al.  Fusion of PET and MRI for staging of uterine cervical cancer: comparison with contrast-enhanced 18F-FDG PET/CT and pelvic MRI[J]. Clin Imaging, 2014, 38(4): 464-469.   doi: 10.1016/j.clinimag.2014.02.006
[10] Devine C, Viswanathan C, Faria S, et al.  Imaging and staging of cervical cancer[J]. Semin Ultrasound CT MR, 2019, 40(4): 280-286.   doi: 10.1053/j.sult.2019.03.001
[11] Xiao ML, Yan BC, Li Y, et al.  Diagnostic performance of MR imaging in evaluating prognostic factors in patients with cervical cancer: a meta-analysis[J]. Eur Radiol, 2020, 30(3): 1405-1418.   doi: 10.1007/s00330-019-06461-9
[12] Nakamura K, Okumura Y, Kodama J, et al.  The predictive value of measurement of SUVmax and SCC-antigen in patients with pretreatment of primary squamous cell carcinoma of cervix[J]. Gynecol Oncol, 2010, 119(1): 81-86.   doi: 10.1016/j.ygyno.2010.04.020
[13] Eisenhauer EA, Therasse P, Bogaerts J, et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228-247.   doi: 10.1016/j.ejca.2008.10.026
[14] Wang DY, Zhao CH, Fu L, et al.  Primary clear cell adenocarcinoma of the cervix: a clinical analysis of 18 cases without exposure to diethylstilbestrol[J]. Obstet Gynecol Int, 2019, 2019: 9465375-.   doi: 10.1155/2019/9465375
[15] Xue FY, Lin LL, Dehdashti F, et al.  F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy[J]. Gynecol Oncol, 2006, 101(1): 147-151.   doi: 10.1016/j.ygyno.2005.10.005
[16] Chung HH, Cheon GJ, Kang KW, et al.  Preoperative PET/CT FDG standardized uptake value of pelvic lymph nodes as a significant prognostic factor in patients with uterine cervical cancer[J]. Eur J Nucl Med Mol Imaging, 2014, 41(4): 674-681.   doi: 10.1007/s00259-013-2626-1
[17] Gandy N, Arshad MA, Park WHE, et al.  FDG-PET imaging in cervical cancer[J]. Semin Nucl Med, 2019, 49(6): 461-470.   doi: 10.1053/j.semnuclmed.2019.06.007
[18] Akkas BE, Demirel BB, Dizman A, et al.  Do clinical characteristics and metabolic markers detected on positron emission tomography/computerized tomography associate with persistent disease in patients with in-operable cervical cancer?[J]. Ann Nucl Med, 2013, 27(8): 756-763.   doi: 10.1007/s12149-013-0745-1
[19] Yoo J, Choi JY, Moon SH, et al.  Prognostic significance of volume-based metabolic parameters in uterine cervical cancer determined using 18F-fluorodeoxyglucose positron emission tomography[J]. Int J Gynecol Cancer, 2012, 22(7): 1226-1233.   doi: 10.1097/IGC.0b013e318260a905
[20] Onal C, Guler OC, Reyhan M, et al.  Prognostic value of 18F-fluorodeoxyglucose uptake in pelvic lymph nodes in patients with cervical cancer treated with definitive chemoradiotherapy[J]. Gynecol Oncol, 2015, 137(1): 40-46.   doi: 10.1016/j.ygyno.2015.01.542
[21] Kim DH, Kim WT, Bae JS, et al.  Maximum standardized uptake value of pelvic lymph nodes in [18F]-fluorodeoxyglucose positron emission tomography is a prognostic factor for Para-aortic lymph node recurrence in pelvic node-positive cervical cancer treated with definitive chemoradiotherapy[J]. Int J Gynecol Cancer, 2016, 26(7): 1274-1280.   doi: 10.1097/IGC.0000000000000772
[22]

Calles-Sastre L, Mucientes-Rasilla J, San-Frutos Llorente LM, et al. Prognostic significance of metabolic tumor volume and total lesion glycolysis in patients with advanced cervical carcinoma[J/OL]. Rev Esp Med Nucl Imagen Mol (Engl Ed), 2019, 38(1): 17−21[2022-02-13]. https://www.sciencedirect.com/science/article/abs/pii/S2253654X1830043X?via%3Dihub. DOI: 10.1016/j.remn.2018.08.001.
[23] Yilmaz B, Dağ S, Ergul N, et al.  The efficacy of pretreatment and after treatment 18F-FDG PET/CT metabolic parameters in patients with locally advanced squamous cell cervical cancer[J]. Nucl Med Commun, 2019, 40(3): 219-227.   doi: 10.1097/MNM.0000000000000969